Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors - PubMed (original) (raw)

Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.

Rai SK, Bril F, Hatch HM, Xu Y, Shelton L, Kalavalapalli S, Click A, Lee D, Beecher C, Kirby A, Kong K, Trevino J, Jha A, Jatav S, Kriti K, Luthra S, Garrett TJ, Guingab-Cagmat J, Plant D, Bose P, Cusi K, Hromas RA, Tischler AS, Powers JF, Gupta P, Bibb J, Beuschlein F, Robledo M, Calsina B, Timmers H, Taieb D, Kroiss M, Richter S, Langton K, Eisenhofer G, Bergeron R Jr, Pacak K, Tevosian SG, Ghayee HK. Rai SK, et al. Metabolism. 2020 Sep;110:154297. doi: 10.1016/j.metabol.2020.154297. Epub 2020 Jun 18. Metabolism. 2020. PMID: 32562798 Free PMC article.

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.

Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E. Hadoux J, et al. Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5. Int J Cancer. 2014. PMID: 24752622